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Appendix A 
Melanoma direct medical costs by treatment interventions and care setting  
Study Intervention/treatment Total costs, $ Per-patient cost, $ 
U.S. Studies    
Tsao et al. (1998)1 Annual cost diagnosis 43,902,630  1,089 
 Surgery and pathology 85,009,501  6,251 
 External radiation 50,733,216  20,132 
 Adjuvant interferon 250,133,832  46,321 
 Chemotherapy 89,612,784  12,276 
 Follow-up 53,527,882  1,228 
 Terminal care 326,397,600  44,712 
Bickers et al. (2006)2 Hospital inpatient 43,855,000  4,216a 
 Hospital, outpatient 95,228,000  2,204a 
 Hospital emergency department 1,253,000  155a 
 Office visits 126,553,000  214a 
 Prescription drugs 97,734,000  NA 
Davis et al. (2009)3,b Hospital costs 165,083,785 25,515 
 Skilled-nursing facility costs 55,160,675 8,526 
 Emergency room costs 3,191,186 493 
 Office visit costs 87,322,129 13,496 
 Home healthcare costs 23,566,002 3,642 
 Hospice costs 31,183,267 4,820 
 Other outpatient or ancillary costs 108,028,678 16,697 
Non-U.S. studies    
Mathers et al. (1998)4 Hospital 15,219,507 2,341c 
 General practitioner visits 17,497,256 33a 
 Specialist visits 18,739,665 35a 
 Pharmaceuticals 1,035,341 NA 
 Nursing home 414,136 41,414 
 Allied health 2,070,681 18a 
O'Dea (2000)5  Hospital costs 2,114,034 2,072c 
 Nonhospital costs 7,307,472 NA 
Nilsson et al. (2003)6 Hospital inpatient care 1,396,120 6,261 
 Hospital ambulatory care 1,470,020 574 
 Primary health care 52,842 76 
 Pharmaceuticals 168,073 NA 
Stang et al. (2007)7,d Hospitalization (melanoma) 75,886,592 3,710c 
 Hospitalization (melanoma in-situ) 3,241,038 3,274 
Chevailer et al. (2008)8 Total hospital 74,131,425 1,728c 
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Study Intervention/treatment Total costs, $ Per-patient cost, $ 
  Surgery 27,941,908 2,970c 
  Chemotherapy 12,207,239 1,167c 
  Radiation therapy 890,076 318c 
  General care 33,092,202 1,634c 
  Follow-up 14,465,193 1,029c 
  Transfusion 193,540 935c 
  Palliative care 4,850,881 6,164c 
  Other 13,582,587 2,613c 
Tinghog et al. (2008)9 Inpatient care 9,854,427 6,042e 
 Outpatient care 19,772,204 2,263 
 Primary care 198,864 208e 
Morris et al. (2009)10 General practitioner consultations 868,324 125 
 Inpatient care 12,439,087 3,251a 
 Day cases 2,757,946 504a 
 Outpatient attendances 21,221,017 122a 
 Patient costs 6,608,836 954 
O'Dea (2009)11 Hospital costs 2,625,989 1,937c 
 Lab test 85,167 44 
 General practitioner consultations 177,432 97 
 Other nonhospital costs 1,135,563 568 
Leiter et al. (2009)12 Detection and follow-up (Germany) 635,726 3,117f 
  Detection and follow-up (U.S.) 1,869,184 9,162 
Note: All costs are in 2010 U.S. dollars. 
a Per visit  
b Annual costs are estimated by taking weighted average of monthly cost by stage and multiplying by 12. 
c Per stay  
d Costs are estimated by taking the average of the three estimates reported in the paper. 
e Per episode  
f Per recurrence 
NA, not available 
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